Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug cocktail shows promise for tough leukemia in younger patients

NCT ID NCT04269213

First seen Nov 14, 2025 · Last updated May 20, 2026 · Updated 23 times

Summary

This study tests a chemotherapy drug called CPX-351 in people under 60 with secondary acute myeloid leukemia (AML), a type of leukemia that develops after other bone marrow diseases or cancer treatments. The goal is to see how many patients achieve complete remission. 21 participants will receive the treatment and be monitored for response and side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Allegheny Health Network Cancer Institute - West Penn Hospital

    Pittsburgh, Pennsylvania, 15224, United States

  • Roswell Park Cancer Institute

    Buffalo, New York, 14263, United States

  • SUNY Upstate Medical Center

    Syracuse, New York, 13210, United States

  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198, United States

Conditions

Explore the condition pages connected to this study.